• Rosewood Hong Kong (No.1) has once again been named The World’s Best Hotel 2026
• The list celebrates hotels from 22 destinations across six continents, with Europe leading the way with 21 winning hotels
• Chablé Yucatán (No.9) in Mexico wins the Bombay Sapphire Eco Hotel Award, audited by the Sustainable Restaurant Association
• In its second year, the Johnnie Walker Art of Design Award is presented to Hôtel du Couvent (No.38) in Nice, France
• James McBride, founder of Nihi Hotels, is celebrated with the SevenRooms Icon Award
• The Best Boutique Hotel Award is awarded to Passalacqua (No.5) in Lake Como, for a third year
• Patina Osaka in Japan (No.33) wins the Nikka Best New Hotel Award
• Other accolades include Ferrari Trento Most Admired Hotel Group Award, awarded to Rosewood; WhistlePig Highest Climber Award goes to Las Ventanas al Paraíso (No.25) in Los Cabos, Mexico; Casa Maria Luigia (No.18) in Modena, Italy wins the Lavazza Highest New Entry Award; and the Best Beach Hotel Award goes to Atlantis The Royal (No.4) in Dubai
• The Fifth Avenue Hotel (No.78) in New York City received the American Express Travel One to Watch Award and Switzerland’s Badrutt’s Palace (No.36) was honoured with the SeiBellissimi Art of Hospitality Award

PARIS, Sept. 15, 2026 /PRNewswire/ — The list of The 50 Best Hotels has been revealed at a prestigious awards ceremony in Paris. The unveiling recognises exceptional and pioneering hospitality experiences from across the globe.

See the full list of The 50 Best Hotels 2026 here

Rosewood Hong Kong (No.1) has once again been recognised as The World’s Best Hotel, following its ranking as No.1 in 2025 and No.3 in 2024. The No.2 spot goes to Capella Bangkok and Four Seasons Bangkok at Chao Phraya River ranks at No.3. Asia has 18 hotels including four in Japan: Aman Tokyo (No.11), Bulgari Tokyo (No.24), Patina Osaka (No.33) and Park Hyatt Kyoto (No.37).

Europe leads the way with 21 winning hotels, including six in Italy and France, four in the UK and one in Greece, Monaco, Switzerland and Türkiye. The highest-ranking European entry is Passalacqua (No.5) in Lake Como.

North America lists six properties and South America has two hotels. Oceania has one hotel included, whereas Africa is home to two.

Media Contact: [email protected]

Media Centre: https://mediacentre.the50.com/ 

SOURCE The 50

This press release is issued pursuant to the provisions of Section 18 paragraph 3 of the Dutch Decree on public takeover bids (Besluit openbare biedingen Wft) (the “Decree“) in connection with the cash offer by NNS Holding (Cyprus) Limited (“NNS“) for all the issued and outstanding shares in the capital of OCI N.V. (“OCI” or the “Company“) (the “Offer“).

AMSTERDAM, Sept. 16, 2026 /PRNewswire/ — OCI (Euronext: OCI) has taken note of the press release issued by NNS on 14 September 2026 in which it formally announced the launch of the Offer by means of publication of its offer memorandum available on NNS’s website at https://nnsholding.com/. In connection with the launch of the Offer, OCI announces that today it has published its Position Statement regarding the Offer as required pursuant to Section 18 of the Decree.

OCI further announces that also today, in accordance with the Decree, it has convened an Extraordinary General Meeting of shareholders (“EGM“) to be held on 30 October 2026 at 10:00 a.m. CET to discuss the Offer. In addition, at the EGM the shareholders will be asked to vote on (i) the proposed strategic combination between OCI and Orascom Construction PLC, and (ii) the OCIN Sale (both as further described in the explanatory notes to the agenda of the EGM).

A copy of the Position Statement, the notice and agenda with explanatory notes for the EGM and related materials are available on OCI’s website at https://oci-global.com/shareholder-meetings/.

ABOUT OCI GLOBAL

Learn more about OCI at www.oci-global.com. You can also follow OCI on LinkedIn.

SOURCE OCI Global

• The fifteen-month dataset represents the final analysis from the Phase 1/2 study
• At the Month 15 primary timepoint, SKY-0515-treated patients showed a +1.59-point difference in Composite Unified Huntington’s Disease Rating Scale (cUHDRS) change from baseline versus overlap-weighted external natural history control
• Differences favoring SKY-0515 were statistically significant across all four cUHDRS components – Total Functional Capacity, Total Motor Score, Symbol Digit Modalities Test and Stroop Word Reading Test – and cUHDRS differences favored SKY-0515 at every prespecified timepoint in the study
• SKY-0515 has shown consistent average reductions in mutant huntingtin protein (mHTT) throughout the study of more than 60% at the 9 mg dose  
• SKY-0515 has shown consistent average reductions in PMS1 mRNA of more than 25% at the 9 mg dose
• The Company’s Phase 1/2 program and global Phase 2/3 FALCON-HD 004-ANZ + 004-WW pivotal program for Huntington’s disease now have enrolled over 200 patients across twenty trial sites in ten countries.

BOSTON, Sept. 16, 2026 /PRNewswire/ — Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, today announced final fifteen-month results from its Phase 1/2 clinical trial evaluating SKY-0515, an investigational oral treatment for Huntington’s disease (HD).

The Phase 1/2 patient study is a randomized, double-blind, placebo-controlled parallel-group study evaluating two dose levels of SKY-0515 in patients over twelve weeks, followed by a twelve-month blinded Extension period during which all participants receive active treatment at either a low or high dose (4mg or 9mg), with the majority of patients on the 9 mg dose.

At Month 15, the primary timepoint, patients treated with SKY-0515 improved on the cUHDRS by an average of 0.94 points from where they started, while a comparison group of untreated patients from the Enroll-HD natural history database declined by an average of 0.65 points. The gap between the two groups was 1.59 points (95% CI: 1.09, 2.09; p<0.001).

SKY-0515 patients also did better than the comparison group on each of the four measures that make up the cUHDRS: daily function (Total Functional Capacity, +0.98 points), movement (Total Motor Score, −9.38 points, where a lower score is better), processing speed (Symbol Digit Modalities Test, +4.15 points) and reading speed (Stroop Word Reading Test, +4.18 points). All differences were statistically significant.

Table 1. Change from baseline at Month 15 in cUHDRS and its components, SKY-0515 versus overlap-weighted external control

CI = confidence interval; SE = standard error.

The same pattern held throughout the study. At every scheduled checkpoint, SKY-0515 patients were doing better on the cUHDRS than the comparison group: 0.66 points at Month 3, 0.78 points at Month 6, 1.04 points at Month 9, 0.79 points at Month 12 and 1.59 points at Month 15. The difference was statistically significant from Month 9 onward.

On average, SKY-0515-treated patients’ cUHDRS scores held at or above their baseline level at every assessment through Month 15, while the external comparison group’s average score declined from Month 6 onward.

Table 2. Change from baseline in cUHDRS by timepoint, SKY-0515 versus overlap-weighted external control

CI = confidence interval; SE = standard error. See footnote¹ for data analysis discussion.

SKY-0515 has shown consistent average reductions of more than 60% mutant huntingtin protein (mHTT) and 25% PMS1 mRNA in patients at the 9 mg dose throughout the study. Mutant huntingtin is the primary protein responsible for HD pathology, while PMS1 is a key driver of somatic CAG repeat expansion associated with disease progression.

SKY-0515 has demonstrated excellent central nervous system exposure and has been generally well tolerated across all dose levels studied through fifteen months of treatment, with no treatment-related SAEs. 

“Skyhawk’s Phase 1/2 results are extremely encouraging clinical data. A 1.59-point cUHDRS difference versus a rigorously weighted natural history control at fifteen months is exactly the type of signal the field looks for in early studies of a potentially effective therapeutic agent. The consistent effects on function, motor and cognitive measures need to be further studied in ongoing placebo-controlled studies but it is an exciting step forward for HD and the program,” said Dr. Samuel Frank, Director of the Huntington’s Disease Society of America Center of Excellence at Beth Israel Deaconess Medical Center. “SKY-0515’s dual reduction of mHTT and PMS1 addresses two core pathogenic mechanisms of Huntington’s disease. If these findings are confirmed in the ongoing Phase 2/3 FALCON-HD pivotal program, the impact on people living with HD across the world could be profound.”

“For almost two decades, I have fought as an advocate for Huntington’s disease patients, bearing witness to countless heartbreaking trial setbacks that have let our families down. To finally see results like these—patients experiencing improvements in function, movement, and cognition — is what we have been hoping and waiting for,” said Katie Jackson, Chief Executive Officer of Help 4 HD International. “What makes SKY-0515 especially exciting is that it is a pill, taken once a day at home. Every step forward in HD matters and we celebrate all of them, but a therapy that is noninvasive and does not require care in a specialized center has the potential to reach so many more patients – in rural communities, in families who can’t travel, and across the world where care is hard to come by.

My husband didn’t get a treatment in time. I am hopeful that my children and the children of thousands of families like ours will. We are the generation of change, and Skyhawk’s drug, if these promising results are fully confirmed in future trials, is what change looks like.”

“The completion of this Phase 1/2 study with SKY-0515, showing statistically significant clinical benefit across every cUHDRS component, is a powerful demonstration of what Skyhawk’s SKYSTAR^® platform can achieve: a daily pill, taken at home, that modifies RNA splicing to lower disease-causing proteins in the CNS and systemically throughout the body,” said Sergey Pauskin, Co-founder and Head of R&D at Skyhawk. “We are applying the same platform to a series of challenging neurological diseases now advancing toward human trials, and the data from SKY-0515 confirms that the possibilities of extraordinary novel drugs generated by Skyhawk’s SKYSTAR platform are very exciting.”

Huntington’s disease is a rare, hereditary, and ultimately fatal neurodegenerative disorder affecting more than 40,000 symptomatic individuals in the United States, with hundreds of thousands impacted worldwide. There are currently no approved therapies shown to slow or halt disease progression.

SKY-0515 is an orally administered investigational small molecule RNA splicing modifier developed using the company’s proprietary SKYSTAR platform. SKY-0515 is designed to reduce both mHTT and PMS1 proteins.

The worldwide Phase 2/3 FALCON-HD-004-WW pivotal study is now active across more than ten countries and twenty clinical sites. SKY-0515’s Phase 1/2 and FALCON-HD pivotal studies have now enrolled more than 200 patients.

Skyhawk expects to advance additional novel therapies targeting rare neurological diseases with no approved disease-modifying treatment into clinical development by the end of 2027.

About the Fifteen-Month Analysis
Phase 1/2 cUHDRS LS mean change from baseline versus external control at 3, 6, 9, 12 and 15 months, and cUHDRS subcomponents LS mean change from baseline versus external control at 15 months, were estimated via overlap-weighted ANCOVA for patients receiving SKY-0515 once daily. Nominal timepoints are anchored to a participant’s first dose of SKY-0515 (Day 1 to Month 3: n=24, Month 6: n=20, Month 9: n=20, Month 12: n=18, Month 15: n=15). Overlap-weighted propensity score weighting was performed using Enroll-HD, 2CARE and CREST-E datasets (Month 3: n=21, Month 6: n=180, Month 9: n=588, Month 12: n=3569, Month 15: n=1337).

Participants received placebo, 3 mg or 9 mg during the first 3 months; afterwards, all participants received 4 mg or 9 mg following Extension-phase randomization. The Month 15 decline in participants partly reflects study design, as the 12-month Extension period caps SKY-0515 exposure at 12 months for participants who initially received 3 months of placebo.

The primary analysis includes all eligible participants with an available Month 15 cUHDRS assessment. Per the study’s statistical analysis plan, a small number of participant-timepoints were excluded following a qualifying intercurrent event — onset of an unrelated medical condition, initiation of a medication that could confound assessment of treatment effect, or a change in background Huntington’s disease therapeutic intervention.

About SKY-0515’s Phase 1/2 Clinical Program
SKY-0515’s Phase 1/2 clinical trial is a first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SKY-0515 in healthy volunteers and patients with early-stage Huntington’s disease (HD).

The trial consists of three parts. Parts A and B evaluated SKY-0515 in Healthy Volunteers. Part C is a randomized, double-blind, placebo-controlled parallel-group study evaluating two dose levels of SKY-0515 in patients with early-stage HD (HD-ISS Stage 1, Stage 2, or mild Stage 3) over 84 days, followed by a twelve-month blinded Extension period during which all participants receive active treatment at either a low or high dose.

Study assessments include measurements of mutant HTT protein, PMS1 mRNA, and cUHDRS.  Enrollment and treatment in the Phase 1/2 study are complete, and the fifteen-month analysis represents the final clinical dataset from the study.

About SKY-0515’s Phase 2/3 FALCON-HD (004-ANZ and 004-WW) Pivotal Program
The FALCON-HD pivotal program (NCT06873334 and NCT07378644) is a randomized, double-blind, placebo-controlled, dose-ranging study evaluating the pharmacodynamics, safety and efficacy of SKY-0515. Eligible patients receive once-daily oral SKY-0515 at one of three dose levels or placebo.

FALCON-HD 004-ANZ enrolled 144 participants with Stage 2 and Stage 3 HD across sites in Australia and New Zealand. Enrollment is complete.

FALCON-HD 004-WW plans to enroll approximately 600 participants with Stage 2 and Stage 3 HD across more than 40 sites worldwide and is actively recruiting.

Additional information regarding FALCON-HD, including participating sites and eligibility criteria, is available at ClinicalTrials.gov and www.FALCON-HD.com.

About Skyhawk Therapeutics
Skyhawk Therapeutics is a clinical-stage biotechnology company leveraging its proprietary SKYSTAR^® platform to discover and develop small molecule RNA-modulating therapies for the world’s most intractable diseases. For more information, visit www.skyhawktx.com.

Skyhawk Contact
Maura McCarthy
Head of Corporate Development
[email protected] 

¹Phase 1/2 cUHDRS LS mean change from baseline vs. external control at 3, 6, 9, 12 and 15 months, estimated via overlap-weighted ANCOVA, for patients receiving SKY-0515 once-daily. Nominal timepoints are anchored to each participant’s first dose of SKY-0515 (Day 1 to Month 3: n=24, Month 6: n=20, Month 9: n=20, Month 12: n=18, Month 15: n=15). Participants received placebo, 3 mg or 9 mg during the first 3 months; afterwards, all participants received 4 mg or 9 mg following Extension-phase randomization. Overlap-weighted propensity score weighting was performed using Enroll-HD, 2CARE and CREST-E datasets (Month 3: n=21, Month 6: n=180, Month 9: n=588, Month 12: n=3569, Month 15: n=1337).

Note: The Month 15 decline in participants partly reflects study design, as the 12-month Extension period caps SKY-0515 exposure at 12 months for the participants who initially received 3 months of placebo. The primary analysis includes all eligible participants with an available Month 15 cUHDRS assessment. Per the study’s statistical analysis plan, a small number of participant-timepoints were excluded following a qualifying intercurrent event — onset of an unrelated medical condition, initiation of a medication that could confound assessment of treatment effect, or a change in background Huntington’s disease therapeutic intervention.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/skyhawk-therapeutics-announces-final-fifteen-month-results-from-phase-12-clinical-trial-of-sky-0515-in-huntingtons-disease-patients-302879424.html

SOURCE Skyhawk Therapeutics

NYSE issues a pre-market daily advisory direct from the trading floor.

NEW YORK, Sept. 15, 2026 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Ashley Mastronardi delivers the pre-market update on September 15th

• Perk is looking to accelerate its growth in the U.S.
  • Announcement comes after the launch of Perk Spend in Europe, where up to 40% of new deals are for the combined Travel and Spend offering.
  • Perk’s research found that one in four U.S. companies still have no formal look for managing spend.
  • Nikita Miller, Perk’s Chief Product Officer, will join NYSE Live to discuss how the solution is bringing control and flexibility to finance leaders.
• ServiceNow President Amit Zavery will join NYSE Live.
  • The company says that its AI Control Tower, Context Engine, and Shift Zero solutions solve the biggest questions customers have.
  • ServiceNow (NYSE: NOW) is looking to guide enterprises through the new tech ecosystem, where AI agents are moving from answering questions to taking action.
• The U.S. 10-Year Treasury yield surpasses 5% and hits highest level since 2007.
  • The move comes as the Federal Reserve commences its two-day meeting, with a decision on interest rates due Wednesday.
  • As of 8 a.m. ET, ICE Brent Crude is trading at $106 a barrel amid the ongoing conflict in the Middle East.

Opening Bell
Ingram Micro (NYSE: INGM) marks their 2026 Capital Markets Day

Closing Bell
Jackson Financial  (NYSE: JXN) celebrates five years of being listed on the NYSE

For market insights, IPO activity, and today’s opening bell, download the NYSE TV App and check out the NYSE YouTube: TV.NYSE.com and YouTube.com/@NYSEofficial

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/perk-brings-its-spend-platform-to-us-nyse-content-update-302879142.html

SOURCE New York Stock Exchange

GOTHENBURG, Sweden, Sept. 16, 2026 /PRNewswire/ — Minesto’s CEO Dr Martin Edlund presents today at Aktiedagen i Stockholm by Aktiespararna, 15 September 2026

The event is livestreamed, and Minesto will be presenting at 18.30 CEST: 

Aktiespararna

Contact

Cecilia Sernhage, Chief Communications Officer
+46 735 23 71 58
[email protected] 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/minesto-ab/r/minesto-presents-today-at-aktiedagen-i-stockholm,c4396487

View original content:https://www.prnewswire.com/apac/news-releases/minesto-presents-today-at-aktiedagen-i-stockholm-302879390.html

SOURCE Minesto AB

New specialized and agentic AI across Autodesk Forma, Autodesk Fusion, and Autodesk Flow turns connected industry data and project context into project intelligence customers can act on 

LAS VEGAS, Sept. 16, 2026 /PRNewswire/ — At Autodesk University 2026, Autodesk (NASDAQ: ADSK) previewed new agentic AI across its three industry clouds: Autodesk Forma for Architecture, Engineering, and Construction; Autodesk Fusion for Design and Manufacturing; and Autodesk Flow for Media and Entertainment. Together, these new capabilities are shaping the next generation of Autodesk Assistant, extending Autodesk’s agentic AI experience across products, projects, and teams rather than inside a single tool, and drawing on connected project data to understand not just the question being asked, but the project behind it.

Autodesk Assistant is generally available today across many Autodesk products, including Fusion, Forma, and Flow, where it helps customers work with Autodesk AI inside the tools they already use. The next-generation experience extends beyond any single product. Rather than requiring professionals to know which Autodesk product or AI capability to reach for, the next generation experience starts from what they are trying to accomplish, brings forward the relevant information and capabilities, and keeps professionals in control. 

This next-generation experience is designed to connect project intelligence with the right Autodesk capabilities across products, projects, and teams, including through a standalone experience planned for 2027.

“The constraint in our industries has never been about ideas. It’s capacity,” said Andrew Anagnost, president and CEO of Autodesk. “And for Design and Make professionals, ‘probably right’ is wrong because their work has consequences in the real world. Our three industry clouds, Forma, Fusion, and Flow, connect the people, data and workflows that make industries work. Autodesk Assistant is how we bring intelligence to customers today, and the next generation will extend that experience across products, projects and teams. And because that intelligence is grounded in more than four decades of Autodesk industry expertise, we can bring customers the right capabilities at the right moment, so they can focus on the problem they need to solve, not the product they need to solve it.”

Autodesk’s advantage is not just understanding what a customer is trying to do. It is combining project intelligence with the specialized design, engineering, simulation, manufacturing, and production capabilities required to turn intent into trusted, real-world outcomes. General-purpose AI can reason across many kinds of information; Autodesk can ground that reasoning in the geometry, constraints, physics, processes, and project history that determine whether something can actually be designed, built, manufactured, or produced.

Why project context and industry expertise matter 

Design and Make AI has to do something harder: understand the specialized context and constraints of real-world projects, such as buildings, infrastructure, products, manufacturing processes, characters, scenes, schedules, specifications, and the relationships between all of them.

Autodesk’s three industry clouds supply that context. Forma connects data and workflows across architecture, engineering and construction. Fusion connects design and manufacturing. Flow connects media and entertainment. Together with more than four decades of Autodesk industry expertise, they create what the company calls project intelligence: actionable intelligence drawn from connected project data, industry context and AI.

The difference becomes tangible when something changes. Consider a structural change to a building. The next generation of Assistant can understand that change in the context of the project, identify its downstream impacts on fabrication, schedule, cost, construction sequencing, and operations, and bring forward the Autodesk capabilities needed to act. Instead of simply describing the problem, Assistant can connect project intelligence to the precise design, engineering, and production tools teams rely on to evaluate options and move toward a trusted, buildable outcome.

“Project teams don’t work in one tool or one part of a project, and the next generation of Autodesk Assistant reflects that,” said Marius Jablonskis, Digital Transformation Leader at Norconsult, a pan-Nordic interdisciplinary consulting firm that specializes in engineering, architecture, and digital expertise. “The potential is to bring the right project context into the workflow so teams can understand what needs attention and act on it more easily. We also see real value in being able to bring our own tools and intelligence into the experience alongside Autodesk’s.”

What the next generation of Autodesk Assistant does

The next-generation Assistant is built around three priorities:

• Understand what needs attention. Personal Pulse surfaces prioritized issues and insights across projects. Assistant Spaces gives teams and their agents a focused environment to investigate a problem, collaborate on it, and see its downstream effects.
• Act across workflows. Assistant brings Autodesk’s specialized design, engineering, and creative AI together with the precise capabilities professionals rely on to simulate, manufacture, and produce their work, turning intent into trusted, reviewable outcomes through natural-language and voice interaction.
• Bring your own intelligence. Assistant Builder lets customers connect their own AI agents, tools and trusted partner services to Autodesk project context, with support planned for third-party agents from the Design & Make Marketplace.

Behind the experience, Autodesk AI Orchestrator evaluates models based on the needs of a particular task, including accuracy, speed, security, and cost, allowing Autodesk to draw on different forms of intelligence rather than relying on a single model for every problem.

The result is an intelligence layer that connects reasoning with action across Autodesk’s Design and Make Platform and industry clouds. It combines project intelligence with the specialized AI and precise capabilities customers rely on to turn ideas into real-world outcomes. Autodesk Assistant is available inside products customers use today and will extend across products, projects, and teams through the next generation of Assistant.

Built for professional work

Autodesk Assistant is grounded in actual project context and, like every Autodesk AI capability, is evaluated for data integrity, privacy and risk. Autodesk publishes AI Transparency Cards for Autodesk Assistant, covering the data and technologies used, safeguards, and known limitations. Autodesk Assistant is designed to support professional judgment, with appropriate controls and human oversight.

In Autodesk’s 2027 State of Design & Make Report, 70% of Design and Make leaders and experts surveyed said they expect AI to reduce mundane and repetitive work and give them added capacity to focus on the judgment, creativity and expertise the work actually requires.

Availability

Autodesk Assistant is already available today within Autodesk industry clouds and across many Autodesk products, including Fusion, Forma, and Flow. Autodesk is previewing the expanded nextgeneration experience at AU 2026. The next-generation experience is not yet generally available. 

Availability, rollout timing, subscription terms, and regional details for these next-generation capabilities will be announced in 2027.

Frequently asked questions

What are Autodesk Forma, Autodesk Fusion, and Autodesk Flow?

Forma, Fusion, and Flow are Autodesk’s three industry clouds, connecting data, workflows, and AI across the industries Autodesk serves.

Autodesk Forma is the industry cloud for AEC, and Autodesk’s foundation for intelligence for the built world. Forma brings together granular design and project data on a common cloud data foundation, connecting workflows across the building lifecycle and providing rich industry context for specialized and agentic AI. Forma is the future of AEC products like Revit, bringing the capabilities customers rely on today into a more connected, cloud-based, and AI-native way of working.

Autodesk Fusion is the industry cloud for Design and Manufacturing, connecting data and workflows across product design, engineering, manufacturing, and production. Fusion brings teams and disciplines together around connected product data so they can move more seamlessly from idea to manufactured product.

Autodesk Flow is the industry cloud for Media and Entertainment, connecting data and workflows across content creation and production. Flow brings creative teams, production data, and AI together to help customers move more seamlessly from idea to final content.

What is Autodesk Assistant and the next generation of Autodesk Assistant?

Autodesk Assistant is Autodesk’s AI interface for Design and Make, bringing project intelligence into customers’ workflows to help them understand, plan, and act using natural language and project context. It connects customers to Autodesk’s specialized AI and capabilities across their workflows, while keeping professionals in control. Autodesk Assistant is generally available today across many Autodesk products.

The next generation of Autodesk Assistant builds on this foundation with an expanded agentic AI experience designed to connect project intelligence with the right Autodesk capabilities across products, projects, and teams. These expanded capabilities are being previewed at AU 2026, are not yet generally available, and are planned to begin rolling out in 2027.

How is trust built into Autodesk Assistant?

Autodesk Assistant is grounded in actual project context, and as an AI capability, is evaluated for data integrity, privacy and risk. For additional information on the data and technologies used, safeguards, and known limitations, Autodesk publishes an AI transparency card for Assistant.  

What is project intelligence?

Project intelligence is actionable intelligence created from connected project data, industry context, and AI.

It can help teams understand what has changed, identify what needs attention, anticipate downstream impacts, and determine what action to take next. Autodesk Assistant is designed to turn the connected data and context within Autodesk’s industry clouds into project intelligence customers can act on.

How does Autodesk bring AI to the physical world?

Many of the buildings, infrastructure, and products people interact with every day begin as digital models. Autodesk connects AI to the industry data, project context, and professional workflows used to design, engineer, build, manufacture, and operate them. That allows Autodesk to combine AI reasoning with the geometry, constraints, physics, processes, and precise capabilities that determine whether an outcome can actually be made in the real world. Autodesk is working toward a continuous loop in which real-world performance informs what customers design and make next.

What does agentic AI mean at Autodesk?

At Autodesk, agentic AI is AI that uses project context to help professionals understand, plan, and take action toward an intended outcome, not simply answer a question. Autodesk Assistant already brings agentic AI capabilities into Autodesk products today, while the next generation is designed to coordinate information and specialized capabilities across products, projects, and teams.

About Autodesk 

The world’s designers, engineers, builders, and creators trust Autodesk to help them design and make anything. From the buildings we live and work in, to the cars we drive and the bridges we drive over. From the products we use and rely on, to the movies and games that inspire us. Autodesk’s

Design and Make Platform unlocks the power of data to accelerate insights and automate processes, empowering our customers with the technology to create the world around us and deliver better outcomes for their business and the planet. For more information, visit autodesk.com or follow @autodesk. #MakeAnything 

Autodesk is a registered trademark of Autodesk, Inc., and/or its subsidiaries and/or affiliates in the USA and/or other countries. All other brand names, product names, or trademarks belong to their respective holders. Autodesk reserves the right to alter product and services offerings, and specifications and pricing at any time without notice, and is not responsible for typographical or graphical errors that may appear in this document. 

Safe Harbor Statement

The presentations during this event may contain forward-looking statements about our outlook, future results and related assumptions, total addressable markets, acquisitions, products and product capabilities, and strategies. These statements reflect our best judgment based on currently known factors. Actual events or results could differ materially. Please refer to our SEC filings, including our most recent Form 10-K and Form 10-Q filings available at www.sec.gov, for important risks and other factors that may cause our actual results to differ from those in our forward-looking statements.  

The forward-looking statements made in these presentations are being made as of the time and date of their live presentation.  If these presentations are reviewed after the time and date of their live presentation, even if subsequently made available by us, on our website or otherwise, these presentations may not contain current or accurate information. We disclaim any obligation to update or revise any forward-looking statements. 

Statements regarding planned or future development efforts for our products and services are not intended to be a promise or guarantee of future availability of products, services, or features but merely reflect our current plans and based on factors currently known to us. Purchasing decisions should not be made based upon reliance on these statements. 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/autodesk-advances-agentic-ai-in-its-three-industry-clouds-302877936.html

SOURCE Autodesk, Inc.

By combining artificial intelligence, industry-specific agents and product data, Apogy revolutionizes the way products are designed and developed

PARIS, Sept. 16, 2026 /PRNewswire/ — Lectra announces the launch of Apogy, its cloud-based solution dedicated to product development, a critical phase between garment design and production. Nearly half a century after establishing the global standard for CAD solutions dedicated to the fashion industry, Lectra is opening a new chapter in history with Apogy.

Designed in the age of agentic artificial intelligence, Apogy transforms product development by bringing data, processes and all stakeholders together in a single digital environment. By automating low-value tasks and making information and expertise easier to access, it significantly accelerates product development while enabling teams to focus on innovation, creativity and strategic decision-making.

From its earliest computer-aided design solutions to Modaris, ModarisPGS and Gerber AccuMark, which have become global industry benchmarks, Lectra has continuously supported the transformation of fashion processes. Today, the industry faces increasingly volatile demand, ever-shorter collection cycles, and mounting regulatory and environmental pressures. Against this backdrop of accelerated change, product development required major technological advances to rethink fragmented processes and dispersed data.

Apogy marks a major turning point by delivering, for the first time, a solution capable of thoroughly reinventing this critical phase.

“For fifty years, Lectra has helped transform the fashion industry, particularly by digitizing patternmaking. Today, agentic artificial intelligence gives us the opportunity to take a new step forward and reinvent product development as a whole,” said Maximilien Abadie, Deputy CEO of Lectra. “With Apogy, we are launching the first and only solution designed to bring together all involved parties, data and processes that shape a product. By breaking down silos and streamlining interactions across the entire ecosystem, we enable fashion companies to develop desirable, manufacturable products that meet consumer demand more quickly. Apogy ushers in a new era of product development, where artificial intelligence turns product data into a competitive advantage for fashion players.”

Agentic artificial intelligence opens a new chapter in product development

At the heart of Apogy, agentic artificial intelligence assists teams in decision-making, automates and accelerates development, and builds on decades of industrial know-how. Agentic AI proactively supports teams and acts as a true ally, capable of orchestrating tasks and leveraging the right data.

A new generation of intelligent agents supports teams throughout the development cycle, from the initial idea to an industrialization-ready prototype. Teams can quickly generate and explore new concepts from prompts, sketches or images, while collaborating in real time on product development in a shared environment that provides full traceability of changes. Compatible with all standard market formats, Apogy also streamlines digital prototyping and facilitates approvals through 3D simulations and high-quality photorealistic renderings.

Collaboration and knowledge transfer at the heart of product development

Apogy centralizes all key product development data in a single, secure, shared and continuously updated source. It enables teams, partners and suppliers across the ecosystem to collaborate simultaneously, thereby accelerating approval and production stages.

O’Neills, an Irish sportswear brand, is already reaping the benefits. “For the first time in our history, all our teams are using a single solution. This harmonization eliminates errors linked to data transfers, increases transparency and now enables us to accelerate operations, improve productivity and effectively support our growth,” said David Towell, Senior Manager at O’Neills.

Apogy also helps preserve and disseminate key know-how within organizations. By leveraging existing expertise, the solution reduces dependence on a small number of experts, safeguards critical skills and accelerates team development.

“New generations expect to work with cutting-edge tools. By equipping our teams with Apogy, a solution designed natively for the AI era and featuring advanced capabilities, we are strengthening our ability to attract, develop and retain the next generation of talent in product development roles, particularly in modelling within the Oniverse group,” said Riccardo Romani, Operations Director at Oniverse, an international fashion group comprising several brands, including Calzedonia, Intimissimi and Tezenis.

Designed to evolve continuously and delivered as SaaS, Apogy will continue to expand its artificial intelligence capabilities to automate more tasks, enhance workflows and unlock new performance opportunities.

The result of three years of development and in-depth dialogue with several dozen customers, Apogy is built on a proven understanding of market needs. Its adoption by early customers has already demonstrated both its operational effectiveness and its ability to support the transformation of product development in the fashion industry today.

About Lectra

Lectra sparks customer transformation.

The Group offers solutions that combine software, cutting equipment, data, and services, leveraging advanced technologies, particularly agentic artificial intelligence. By blending deep sector expertise with industrial intelligence, Lectra helps players in the fashion, automotive, and furniture industries rethink their operations.

Listed on Euronext, Lectra reported revenues of €507 million in 2025, including €89 million in SaaS revenues.

For more information, visit lectra.com. 

[email protected]

SOURCE Lectra

ZURICH, Sept. 15, 2026 /PRNewswire/ — The Adecco Group (SIX: ADEN) today announced the global rollout of Agentforce Coworker across 40 plus countries following a successful pilot in the UK and France. Salesforce’s enterprise “AI teammate”, embedded directly in the platform and powered by Anthropic’s Claude, supports work across sales, recruitment and client/candidate engagement workflows.

Today, Denis Machuel, CEO of the Adecco Group, will join Marc Benioff, chair and CEO of Salesforce – alongside the CEOs of Anthropic, NVIDIA and Siemens – as part of the main Dreamforce keynote to discuss human-centric AI.

The Adecco Group has an unlimited Agentforce 360 enterprise agreement with Salesforce, enabling the company to scale agentic AI across its global operations. It has already deployed agentic AI across recruitment workflows in ten countries, representing 50% of Adecco business revenues. This Coworker rollout now extends agentic AI infrastructure into the daily workflows of 27,000 employees, giving colleagues a single point of access to data, systems and organizational knowledge that was previously sat across dozens of tools. Coworker will also draw on context from more than 2.5 million agent-candidate interactions since April 2025.

With Coworker, sales professionals and recruiters can find priority prospects, prepare sales briefs, enrich prospect data and view the status of leads across teams. Recruiters can also select candidates and launch the pre-screening, recruiter or onboarding agent.

Denis Machuel said: “We are seeing the biggest redesign of work since the internet; we need to enable our people with technology and new ways of working. Building on our successful recruitment agentification, the rollout of Coworker means our teams have access to a single interface that knows candidate history, client context for the moment when human judgment matters the most.”

“Our pilot showed strong adoption in a matter of days. It frees up our sales teams’ and recruiters to focus on what only humans can do: richer engagement with candidates and clients.”

For further information please contact:

The Adecco Group Corporate Press Office

Group External Communications of the Adecco Group
[email protected]

Rodrigo Sánchez Flores – Tel: +34 658 06 54 02
Jürg Schneider – Tel: +41 79 876 09 21

About The Adecco Group
The Adecco Group is the world’s leading talent and technology expertise company. Our purpose is making the future work for everyone. Through our three global business units – Adecco, Akkodis and LHH – across 60 countries, we enable sustainable and lifelong employability for individuals, deliver digital engineering consulting to innovate and accelerate business transformation and empower organizations to optimize their workforces. The Adecco Group leads by example and is committed to fostering sustainable employability and supporting resilient economies and communities. The Adecco Group AG is headquartered in Zurich, Switzerland (ISIN: CH0012138605) and listed on the SIX Swiss Exchange (ADEN). https://www.adeccogroup.com/

SOURCE The Adecco Group

SUZHOU, China, Sept. 15, 2026 /PRNewswire/ — Natus Medical Incorporated, the world’s largest pure-play neurodiagnostic company, today announced the launch of the Nicolet EDX EMG system in the People’s Republic of China, marking the first Natus product manufactured and sold in the PRC.

Nicolet EDX is the most comprehensive Natus EMG system, delivering industry-leading performance and advanced capabilities healthcare organizations rely on for confident diagnostic decision-making. On June 18, Nicolet EDX became the first locally manufactured Natus product registered in China after receiving final approval from the National Medical Products Administration.

The launch of the Nicolet EDX system marks an important milestone in the long-term commitment Natus has to China, where healthcare procurement increasingly prioritizes locally manufactured medical technologies. This launch positions Natus to better support hospitals, distributors, clinicians, and patients across the country.

“China has always been a critical geography for Natus, and our new locally manufactured capability builds on our long history of partnership with leading hospitals across China,” said Walter Wang, General Manager, China. “Through our market-leading distribution network, we are strengthening access to advanced Natus neurodiagnostic technologies and services for clinicians and patients in China.”

Designed for routine EMG examinations, complex neuromuscular cases, and advanced diagnostic workflows, Nicolet EDX gives clinicians a comprehensive and scalable platform for confident testing and diagnosis.

“This milestone represents far more than local production. It brings together Natus’ global vision, standards, technology and experience with talent, insight and capabilities through our team in China,” said Wang. “It also demonstrates our long-term commitment to the clinicians and patients we serve in China.”

The EDX system is built in the new Natus office in Suzhou, a historic city that has become one of Eastern China’s industrial hubs. Natus will hold a ceremony in Suzhou on October 27, celebrating the collaboration of this new site and product launch milestone in China.

ABOUT NATUS 

Natus is trusted by healthcare providers around the globe as the solution source to screen, diagnose, and treat disorders affecting the brain and neural pathways. The best-in-class Natus solutions, including service, field support, and education, enable clinicians to advance their standard of care, improving patient outcomes and quality of life. For more information on Natus, please visit natus.com/neuro.

CONTACT INFORMATION:  
Lisa Schuler
Phone: +1 612 528-1332
Email: [email protected]

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/natus-launches-locally-manufactured-nicolet-edx-system-in-china-302879152.html

SOURCE NATUS MEDICAL INCORPORATED

The trailblazing leader will celebrate the U.S. arrival of the vacation brand’s newest Icon Class vacation this November during a Veterans Day naming ceremony in Fort Lauderdale, Florida

MIAMI, Sept. 15, 2026 /PRNewswire/ — Ahead of the boldest family vacation’s arrival to Fort Lauderdale, Royal Caribbean has named retired U.S. Air Force Gen. Lori J. Robinson as the official godmother of Legend of the Seas. A pioneering leader, role model for women in service, and dedicated advocate for individuals and families balancing their careers and homes, Gen. Robinson has spent her career breaking barriers as the nation’s first female combatant commander and former leader of NORAD and NORTHCOM, inspiring generations through her example. As godmother, she will join a longstanding maritime tradition of bestowing safekeeping upon the ship, its crew and the millions of vacationers who will make memories on Legend for years to come.

Following its debut summer in Europe, Legend of the Seas will arrive in Fort Lauderdale this November, where Royal Caribbean will officially welcome the ship to the U.S. during a Veterans Day naming ceremony with Gen. Robinson, the vacation brand’s leaders, crew and vacationers. The celebration on Nov. 11 will mark the ship’s next chapter of delivering the world’s best family vacation while recognizing Gen. Robinson’s groundbreaking leadership and the service of veterans, active-duty service members and military families.

“I am deeply honored to be named godmother of Legend of the Seas and take part in such a special tradition for Royal Caribbean alongside my family,” said Gen. Lori J. Robinson, godmother of Legend of the Seas. “Throughout my career, I have seen the importance of bringing people together in pursuit of a shared purpose, and Legend creates those same connections for families and loved ones. Having the ship’s naming ceremony on Veterans Day makes this especially meaningful to me, and I look forward to recognizing the generations of men and women who have served.”

Built for every type of family and adventurer, Legend delivers the ultimate family vacation with a lineup of unrivaled experiences across thrills, relaxation, dining and entertainment. Vacationers of all ages can experience the most dining at sea with 28 options, including the immersive Royal Railway – Legend Station and multi-course Hollywoodland Supper Club; seven pools; thrills like Crown’s Edge – part skywalk, part zip line 154 feet above the ocean – unparalleled entertainment, including America’s Got Talent LIVE on Legend of the Seas and Roald Dahl’s “Charlie and the Chocolate Factory,” and more.

“Gen. Lori J. Robinson embodies courage, determination and a spirit of service that make her a legend in her own right and a remarkable godmother for Legend of the Seas,” said Michael Bayley, president and CEO, Royal Caribbean. “We are honored to celebrate her incredible legacy as a 37-year Air Force commander who has defied all limits, along with the countless stories of military service across our Royal Caribbean family, from the crew who create unforgettable vacations to the guests who sail with us from around the world.”

From Fort Lauderdale, Legend will deliver 6-night Western Caribbean getaways and 8-night Southern Caribbean vacations to the beaches of Oranjestad, Aruba, and Willemstad, Curacao. Plus, every vacation on Legend will visit Royal Caribbean’s top-rated Perfect Day CocoCay in The Bahamas, featuring crystal-clear waters and white sand beaches, a thrilling waterpark, pools, swim-up bars and more.

Vacations on Legend are open to book on Royal Caribbean’s website.

About Royal Caribbean
Royal Caribbean, part of Royal Caribbean Group (NYSE: RCL), has delivered memorable vacations for more than 50 years. The cruise line’s game-changing ships and signature destinations revolutionize vacations with industry-leading innovations and an all-encompassing combination of experiences, from thrills and ways to chill, to dining and entertainment, for every type of family and vacationer. Voted “Best Cruise Line Overall” for 23 consecutive years in the Travel Weekly Readers Choice Awards, Royal Caribbean makes memories with adventurers across more than 300 destinations in 80 countries on all seven continents, including Perfect Day CocoCay in The Bahamas and Royal Beach Clubs in Paradise Island and Santorini, plus Royal Beach Club Lelepa coming soon.

Media can stay up to date by following @RoyalCaribPR on X and visit www.RoyalCaribbeanPressCenter.com. For additional information or to book, vacationers can visit www.RoyalCaribbean.com, call (800) ROYAL-CARIBBEAN or contact their travel advisor.

SOURCE Royal Caribbean International